Glucocorticoids, Concomitant Immunosuppression, and Pneumocystis jirovecii Pneumonia Prophylaxis Among US Adults

The impact of glucocorticoids, comorbid conditions, and immunosuppressive therapies on Pneumocystis jirovecii pneumonia risk remains understudied, and prophylaxis is underused. Among US adults in TriNetX prescribed glucocorticoids for ≥2 weeks, 44.6% received >20 mg prednisone equivalents daily. Prophylaxis rates were low, with higher glucocorticoid doses associated with lower prophylaxis odds.